Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Avon Retail Strategy BeComing Direct-Sell As Penney’s Minimizes Cosmetics

This article was originally published in The Rose Sheet

Executive Summary

Avon plans to reposition the beComing beauty brand in the U.S. by folding the retail collection into its direct-sell business and ending its partnership with J.C. Penney, which announced it is de-emphasizing cosmetics sales

You may also be interested in...



Sephora Will Launch Shops In JCPenney This Fall

Beauty retailer Sephora is seeking to increase its U.S. presence by partnering with JCPenney to launch a new store within a store concept. The companies announced the deal April 11

Sephora Will Launch Shops In JCPenney This Fall

Beauty retailer Sephora is seeking to increase its U.S. presence by partnering with JCPenney to launch a new store within a store concept. The companies announced the deal April 11

Ultima distribution

Revlon will continue to support its Ultima brand domestically and abroad despite discontinuation of the brand in J.C. Penney, Elizabeth Kenny, senior VP-marketing for Almay and the Portfolio Brands says. Discontinuation will not have a "significant" impact on Revlon's overall business, as business in Penney's represents less than 1% of consolidated sales, exec adds. Statement follows J.C. Penney's announcement that it is downsizing its cosmetics department (1"The Rose Sheet" Feb. 3, 2003, p. 3)...

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

RS010926

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel